Dr. Edward Verrier
Dr. Edward Verrier
Surgery - Thoracic
I specialize in
Surgery - Thoracic
I have been in practice
My answers and insights have
Helped 50 people
Here are kind words from others
Well, My name is Ian Henderson and I'll keep this relatively brief. Two rears ago I needed a heart transplant. This super cool and elusive cat named Dr. Verrier did my heart transplant and I am alive and kicking butt wherever I go. I'm either I'm jogging around Greenlake in Seattle, camping on the coast, or climbing Mount Baker with my new squeeze box and the short but profound memory of meeting my guy, Dr Verrier. He wore a spanking tweed jacket over his labcoat, atop a pair of very stylish Italian loafers and under the type of hat attributed to the rat pack. The guy is some kind of genius, because the stories about this mench are nothing BUT brave and heroic. He takes cases that are too dicey or dangerous for other surgeons. When the chief of cardiac surgery of whatever hospital is at a loss, HE is who they call! He is the specialist of specialists, the pro at the top of the heap of pro's. I've heard a few stories about him flying to different states and different countries to successfully perform dangerous
This Thanksgiving, I wanted to share my appreciation for all that you do! Thank you, doctor! :)
I am located at
Division of Cardiothoracic Surgery
1959 NE Pacific Street, Box 356310
Seattle , WA 98195
1959 N.E. Pacific St.
Seattle , WA 98195-0001
I was educated and trained at
Medical / Graduate School
Tufts University School of Medicine
Dr. Edward Verrier M
I've won the following awards
Top Doctor, Seattle Metropolitan Magazine
Top Doc, Seattle Magazine
Effect of cytokine hemoadsorption on brain death-induced ventricular dysfunction in a porcine model.
J. Thorac. Cardiovasc. Surg., Nov (2012)
Teaching behaviors in the cardiac surgery simulation environment.
J. Thorac. Cardiovasc. Surg., Oct (2012)
Long-term outcome for the surgical treatment of infective endocarditis with a focus on intravenous drug users.
Ann. Thorac. Surg., Jan;93(1):51-7 (2012)
Mitral regurgitation--what is best for my patient?
N. Engl. J. Med., Apr;364(15):1462-3 (2011)
Management of acute regurgitation in left-sided cardiac valves.
Tex Heart Inst J., 38(1):9-19 (2011)
Joint Council on Thoracic Surgical Education: an investment in our future.
J. Thorac. Cardiovasc. Surg., Feb;141(2):318-21 (2011)
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.
J. Thorac. Cardiovasc. Surg., Jul;142(1):89-98 (2011)
Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury.
Arterioscler. Thromb. Vasc. Biol., Nov;30(11):2136-42 (2010)
Predictive value of the Seattle Heart Failure Model in patients undergoing left ventricular assist device placement.
J. Heart Lung Transplant., Sep;29(9):1021-5 (2010)
Consensus statement: minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass.
Heart Surg Forum., Apr;13(2):E116-23 (2010)
Acute valvular regurgitation.
Circulation., Jun;119(25):3232-41 (2009)
Consensus statement: Defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass.
Heart Surg Forum., 11(5):E316-22 (2008)
Characteristics of extracoronary vascular disease in heart transplant recipient.
J Card Surg., 23(5):459-63 (2008 Sep-Oct)
Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy.
Circulation., Nov;116(20):2298-306 (2007)
Translational research: is there a future?
J. Thorac. Cardiovasc. Surg., Jun;133(6):1409-11 (2007)
Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization.
Crit. Care Med., May;35(5):1296-301 (2007)
Is pre-transplant vascular disease a risk factor for mortality and morbidity after heart transplantation?
Eur J Cardiothorac Surg., Mar;31(3):457-61 (2007)
Open-chest management after heart transplantation.
Tex Heart Inst J., 33(3):306-9 (2006)
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview.
Am. Heart J., Aug;152(2):291-6 (2006)
Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients.
Ann. Thorac. Surg., Aug;82(2):486-92 (2006)
Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury.
Circulation., Jul;114(1 Suppl):I270-4 (2006)
Expectant management is safe for cholelithiasis after heart transplant.
J. Heart Lung Transplant., May;25(5):539-43 (2006)
Successful management of asystole with an isolated left ventricular assist device.
J. Heart Lung Transplant., Apr;25(4):490-2 (2006)
Crosstalk between thrombosis and inflammation in lung reperfusion injury.
Ann. Thorac. Surg., Mar;81(3):1061-7 (2006)
Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
J. Thorac. Cardiovasc. Surg., Feb;131(2):352-6 (2006)
A short wholly inside-out reversed vascular graft facilitating difficult aortic anastomosis.
Ann. Thorac. Surg., Oct;80(4):1534-6 (2005)
Evaluation of web-based learning tools: lessons learned from the thoracic surgery directors association curriculum project three-year experience.
Ann. Thorac. Surg., Sep;80(3):802-9; discussion 809-10 (2005)
Pexelizumab -- a C5 complement inhibitor for use in both acute myocardial infarction and cardiac surgery with cardiopulmonary bypass.
Expert Opin Biol Ther., Jun;5(6):833-9 (2005)
Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.
J. Thorac. Cardiovasc. Surg., Dec;128(6):850-9 (2004)
FR167653 diminishes infarct size in a murine model of myocardial ischemia-reperfusion injury.
J. Thorac. Cardiovasc. Surg., Oct;128(4):588-94 (2004)
Activation of the endothelium in cardiac allografts.
J. Heart Lung Transplant., Sep;23(9 Suppl):S229-33 (2004)
FR167653 reduces obliterative airway disease in rats.
J. Heart Lung Transplant., Aug;23(8):985-92 (2004)
Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart.
J. Thorac. Cardiovasc. Surg., Aug;128(2):170-9 (2004)
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
JAMA., May;291(19):2319-27 (2004)
Alpha chemokines regulate direct lung ischemia-reperfusion injury.
J. Heart Lung Transplant., May;23(5):585-91 (2004)
Who moved my heart? Adaptive responses to disruptive challenges.
J. Thorac. Cardiovasc. Surg., May;127(5):1235-44 (2004)
Novel broad-spectrum chemokine inhibitor protects against lung ischemia-reperfusion injury.
J. Heart Lung Transplant., Jan;23(1):128-34 (2004)
Unique considerations for the spinal cord injured patient undergoing cardiac surgery utilizing cardiopulmonary bypass.
J Extra Corpor Technol., Sep;35(3):230-7 (2003)
Endothelial response to cardiopulmonary bypass surgery.
Ann. Thorac. Surg., Nov;66(5 Suppl):S17-9; discussion S25-8 (1998)
Inhibition of nuclear factor-kappa B nuclear localization reduces human E-selectin expression and the systemic inflammatory response.
Circulation., Nov;98(19 Suppl):II282-8 (1998)
Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury.
J. Thorac. Cardiovasc. Surg., Jul;116(1):114-21 (1998)
Prospective trial of catheter irrigation and muscle flaps for sternal wound infection.
Ann. Thorac. Surg., Apr;65(4):1046-9 (1998)
Editorial (pro) re minimally invasive port-access mitral valve surgery.
J. Thorac. Cardiovasc. Surg., Mar;115(3):565-6 (1998)
Endothelial cell injury in cardiovascular surgery: atherosclerosis.
Ann. Thorac. Surg., Mar;63(3):885-94 (1997)
Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response.
Ann. Thorac. Surg., Jan;63(1):277-84 (1997)
Endothelial cell injury in cardiovascular surgery: ischemia-reperfusion.
Ann. Thorac. Surg., Dec;62(6):1868-75 (1996)
Endothelial cell injury in cardiovascular surgery: the procoagulant response.
Ann. Thorac. Surg., Nov;62(5):1549-57 (1996)
Endothelial cell injury in cardiovascular surgery: the pathophysiology of vasomotor dysfunction.
Ann. Thorac. Surg., Oct;62(4):1222-8 (1996)
Endothelial cell injury in cardiovascular surgery.
Ann. Thorac. Surg., Sep;62(3):915-22 (1996)
Replacement of mitral valve posterior chordae tendineae with expanded polytetrafluoroethylene suture: a finite element study.
J Card Surg., 11(2):136-45; discussion 146 (1996 Mar-Apr)
Surgical treatment of myasthenia gravis in two major Middle East teaching hospitals: factors influencing outcome.
Thorax., Feb;51(2):193-6 (1996)
Individual variations in the fibrinolytic response during and after cardiopulmonary bypass.
Thromb. Haemost., Nov;74(5):1293-7 (1995)
CD18-independent mechanism of neutrophil emigration in the rabbit lung after ischemia-reperfusion.
Ann. Thorac. Surg., Nov;60(5):1360-6 (1995)
Changes in cardiovascular surgical approaches to achieve early extubation.
J. Cardiothorac. Vasc. Anesth., Oct;9(5 Suppl 1):10-5 (1995)
Intermediate results from the period of the Congenital Heart Surgeons Transposition Study: 1985 to 1989. Congenital Heart Surgeons Society Database.
Ann. Thorac. Surg., Sep;60(3):505-10 (1995)
Endothelial loss and regeneration in a model of transplant arteriosclerosis.
Transplantation., Jul;60(1):96-102 (1995)
The effect of anterior chordal replacement on mitral valve function and stresses. A finite element study.
ASAIO J., 41(3):M754-62 (1995 Jul-Sep)
Hypothermia reversibly inhibits endothelial cell expression of E-selectin and tissue factor.
J Card Surg., Jul;10(4 Suppl):428-35 (1995)
Modified conduit preparation creates a pseudosinus in an aortic valve-sparing procedure for aneurysm of the ascending aorta.
J. Thorac. Cardiovasc. Surg., Jun;109(6):1049-57; discussion 1057-8 (1995)
University of Wisconsin solution provides superior myocardial preservation compared with Stanford cardioplegic solution.
J. Heart Lung Transplant., 13(6):1099-108 (1994 Nov-Dec)
Inhibition of neutrophil adhesion does not prevent ischemic spinal cord injury.
Ann. Thorac. Surg., Oct;58(4):1064-8 (1994)
Anatomic basis for mitral valve modelling.
J. Heart Valve Dis., Sep;3(5):491-6 (1994)
Expression of E-selectin on coronary endothelium after myocardial ischemia and reperfusion.
J Card Surg., May;9(3 Suppl):437-41 (1994)
Schwannoma of the left atrium: diagnostic evaluation and surgical resection.
Ann. Thorac. Surg., Mar;57(3):743-6 (1994)
Aortic root and valve relationships. Impact on surgical repair.
J. Thorac. Cardiovasc. Surg., Jan;107(1):162-70 (1994)
Acquired immunodeficiency syndrome-related lymphoma of the lung presenting as empyema thoracis.
Ann. Thorac. Surg., Jan;57(1):216-9 (1994)
Porcine aortic leaflet arrangement may contribute to clinical xenograft failure.
ASAIO J., 39(4):918-22 (1993 Oct-Dec)
Clonidine improves perioperative myocardial ischemia, reduces anesthetic requirement, and alters hemodynamic parameters in patients undergoing coronary artery bypass surgery.
J. Cardiothorac. Vasc. Anesth., Aug;7(4):386-95 (1993)
A reduction in accelerated graft coronary disease and an improvement in cardiac allograft survival using low molecular weight heparin in combination with cyclosporine.
J. Heart Lung Transplant., 12(4):634-43 (1993 Jul-Aug)
Infusion of autologous platelet rich plasma does not reduce blood loss and product use after coronary artery bypass. A prospective, randomized, blinded study.
J. Thorac. Cardiovasc. Surg., Jun;105(6):1007-13; discussion 1013-4 (1993)
Dr. Edward Verrier M